

In the Claims:

1-118. (canceled).

119. (Currently amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide is an immunosuppressor.

120. (Currently amended) The isolated polypeptide of Claim 119 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide is an immunosuppressor.

121. (Currently amended) The isolated polypeptide of Claim 119 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);

- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide;
- (c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
- (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide; or~~
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide is an immunosuppressor.

122. (Currently amended) The isolated polypeptide of Claim 119 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide;
- (c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
- (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO:377); lacking its associated signal peptide; or~~
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide is an immunosuppressor.

123. (Currently amended) The isolated polypeptide of Claim 119 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide;
- (c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide is an immunosuppressor.

124. (Currently amended) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377); lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092.

125. (Currently amended) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377).

126. (Currently amended) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide.

127-128. Canceled.

129. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092.

130. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 124 fused to a heterologous polypeptide.

131. (Previously presented) The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

132. (New) An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
(b) the amino acid sequence of the polypeptide of SEQ ID NO: 377; lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide induces chondrocyte redifferentiation.

133. (New) The isolated polypeptide of Claim 132 having at least 85% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
(b) the amino acid sequence of the polypeptide of SEQ ID NO: 377; lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide induces chondrocyte redifferentiation.

134. (New) The isolated polypeptide of Claim 132 having at least 90% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
(b) the amino acid sequence of the polypeptide of SEQ ID NO: 377; lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said polypeptide induces chondrocyte redifferentiation.

135. (New) The isolated polypeptide of Claim 132 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377; lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092; wherein said polypeptide induces chondrocyte redifferentiation.

136. (New) The isolated polypeptide of Claim 132 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377; lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092; wherein said polypeptide induces chondrocyte redifferentiation.